Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy

Ghassan Bandak, Bruce A. Jones, Jian Li, Jerry Yee, Kausik Umanath

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Antibody-mediated anti-glomerular basement membrane (anti-GBM) disease occurs rarely in the presence of another B-cell disorder, membranous nephropathy. The coexistence of these two autoimmune disorders would be anticipated to require differing, specific therapies targeted to each disease process. We describe a case of concomitant membranous nephropathy and anti-GBM disease in which conventional therapy, including steroids, plasmapheresis and cyclophosphamide, failed to attenuate the anti-GBM disease, yet responded to an alternative treatment of rituximab. This B-cell directed, monoclonal, chimeric antibody treatment substantially reduced anti-GBM antibody titers and led to discontinuation of plasmapheresis, while maintaining the remission of membranous nephropathy and anti-GBM disease.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalClinical Kidney Journal
Volume7
Issue number1
DOIs
StatePublished - Feb 2014

Keywords

  • anti CD-20
  • anti-GBM disease
  • Goodpasture syndrome
  • membranous nephropathy, rituximab

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Fingerprint

Dive into the research topics of 'Rituximab for the treatment of refractory simultaneous anti-glomerular basement membrane (anti-GBM) and membranous nephropathy'. Together they form a unique fingerprint.

Cite this